Our finding that PARP-1 regulates CCR6 –work originating in human genetics—lends further support to the hypothesis that PARP-1 could represent a promising anti-inflammatory target in humans, a conclusion of potential importance since PARP-1 inhibitors are already approved for human use in ovarian cancer [8,45]. The gene discussed is CCR6; the disease is ovarian cancer.